SAT0028 Circulating Surfactant Protein-D (SP-D) Molecular Size Profile Differs between Patients with Untreated Axial Spondyloarthritis and Healthy Control Subjects

Autor: Uffe Holmskov, Lene Christiansen, Anne Gitte Loft, Peter Junker, Grith Sorensen, R. Jounblat, D. Fakih, Qihua Tan, Heidi Lausten Munk, Kirsten Ohm Kyvik, L. Ejstrup, Anne Friesgaard Christensen
Rok vydání: 2016
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 75:674.1-674
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2016-eular.1936
Popis: Background Surfactant protein-D (SP-D), an innate immune defence molecule of the collectin family has immune modulatory and anti-microbial effects and is expressed in lungs and on mucosal surfaces. The molecule consists of subunits ordered as trimers, dodecamers and even higher multimers. In healthy adults genes are responsible for the majority of the quantitative variation of SP-D in serum as well as its molecular size distribution 1 . High Molecular weight (HMw) SP-D is suggested to have anti-inflammatory properties, while low Mw (LMw) variants lack this capacity. In spondyloarthritis (SpA) SP-D correlates negatively with hsCRP and positively with patient global assessment. LMw variants have been shown to prevail in serum during inflammatory flares in chronic obstructive pulmonary disease. Objectives To investigate the distribution of SP-D HMw and LMw variants in serum among patients with SpA and controls according to the Met11Thr polymorphism. Methods 34 patients with SpA (age 22–63) according to the ASAS criteria, receiving NSAIDs only and 57 healthy controls (age 10–75) were included (Table 1). Total SP-D in serum was measured by ELISA and SNP rs721917 was genotyped. SP-D molecular size distribution was assessed using gel filtration chromatography. Integration of the area under the curves was performed to determine the ratio between HMw and LMw SP-D in serum. Results SP-D in SpA was in the normal range, 1092 ng/ml (725;1541) vs. controls, 910 ng/ml (494; 1682). Whereas the ratio of HMw:LMw serum SP-D was lower in SpA patients, 0.38 (0.18;0.53) compared to controls 1.49 (0.37; 3.24) even when adjusting for the Met11Thr polymorphism, gender, age, BMI and smoking (Table 2). Conclusions The molecular size distribution of circulating SP-D in patients with SpA is skewed towards preponderance of small size molecular variants. SpA related disease mechanisms may disrupt the multimeric state of SP-D, thereby amplifying the inflammatory burden of the disease. References Leth-Larsen R. J Immunol 2005;174:1532–8 Disclosure of Interest None declared
Databáze: OpenAIRE
Externí odkaz: